APVO Aptevo Therapeutics Inc.
USHealthcareAs of 2026-07-10 16:00
Why APVO matters now
Aptevo Therapeutics Inc. (APVO) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.94 with +0.00% on the session and $8.6M in market capitalization; recent performance reads 1-month +4.94% and YTD -50.48%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-6.7M, and EPS of $-6.41. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -264.2%.
The latest indexable market news headline is "Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors" from Accesswire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Janatpour Mary Jo filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.43
P/S
0.00
EV/EBITDA
-0.00
DCF Value
$5,118.26
FCF Yield
-264.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-198.5%
ROA
-131.9%
ROIC
-166.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-6.7M | $-6.41 |
| Q4 2025 | $0.00 | $-5.8M | $-159.33 |
| FY 2025 | $0.00 | $-26.0M | $-87.27 |
| Q3 2025 | $0.00 | $-7.5M | $-40.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.69
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.